Spring Bank Pharmaceuticals Inc Expected to Earn Q1 2019 Earnings of ($0.72) Per Share (SBPH)

Spring Bank Pharmaceuticals Inc (NASDAQ:SBPH) – Equities research analysts at B. Riley issued their Q1 2019 EPS estimates for shares of Spring Bank Pharmaceuticals in a research report issued to clients and investors on Wednesday, March 13th. B. Riley analyst M. Kumar expects that the company will post earnings of ($0.72) per share for the quarter. B. Riley also issued estimates for Spring Bank Pharmaceuticals’ Q2 2019 earnings at ($0.79) EPS, Q3 2019 earnings at ($0.92) EPS, Q4 2019 earnings at ($1.11) EPS, FY2019 earnings at ($2.73) EPS, FY2020 earnings at ($2.43) EPS, FY2021 earnings at ($4.00) EPS and FY2022 earnings at $0.43 EPS.

Spring Bank Pharmaceuticals (NASDAQ:SBPH) last released its quarterly earnings results on Monday, March 11th. The company reported ($0.33) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.50) by $0.17.

Several other research analysts also recently issued reports on SBPH. Zacks Investment Research raised Spring Bank Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $12.00 price target for the company in a research note on Friday. Cantor Fitzgerald set a $34.00 price target on Spring Bank Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, December 7th. Finally, Chardan Capital set a $45.00 target price on shares of Spring Bank Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, November 30th. One equities research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Spring Bank Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $28.80.

NASDAQ:SBPH opened at $10.85 on Friday. The firm has a market cap of $178.34 million, a PE ratio of -5.80 and a beta of 0.80. Spring Bank Pharmaceuticals has a 52-week low of $8.14 and a 52-week high of $15.73.

Hedge funds have recently made changes to their positions in the stock. Rhumbline Advisers acquired a new position in Spring Bank Pharmaceuticals in the 3rd quarter valued at about $122,000. Blair William & Co. IL acquired a new position in Spring Bank Pharmaceuticals in the 3rd quarter valued at about $123,000. JPMorgan Chase & Co. raised its stake in Spring Bank Pharmaceuticals by 464.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 12,712 shares of the company’s stock valued at $153,000 after purchasing an additional 10,458 shares during the last quarter. Pegasus Asset Management Inc. acquired a new position in Spring Bank Pharmaceuticals in the 4th quarter valued at about $195,000. Finally, Dimensional Fund Advisors LP acquired a new position in Spring Bank Pharmaceuticals in the 4th quarter valued at about $206,000. 43.18% of the stock is owned by hedge funds and other institutional investors.

About Spring Bank Pharmaceuticals

Spring Bank Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapeutics using small molecule nucleic acid hybrid (SMNH) chemistry platform. The company's lead SMNH product candidate is inarigivir soproxil, for the treatment of chronic hepatitis B virus (HBV).

Recommended Story: What is Put Option Volume?

Earnings History and Estimates for Spring Bank Pharmaceuticals (NASDAQ:SBPH)

Receive News & Ratings for Spring Bank Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spring Bank Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.